Cd20-specific antibodies and methods employing same
CA 2897608 C · Owner: Duke University · Inventors: Hamaguchi, Yasuhito; Poe, Jonathan C.; Tedder, Thomas F.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20 as well as pharmaceutical compositions comprising the same The invention further provides methods of using the monoclonal antibodies antigen-binding fragments, and pharmaceutical compositions for example, in methods of depleting B cells or in treating B cell disorders Also provided are cells nucleic acids and methods for producing the monoclonal antibodies
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 7, 2004 and granted July 31, 2018. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 7, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 7, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.